Findings presented at the American College of Cardiology Annual Scientific Session indicate that finerenone's efficacy in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

At the American College of Cardiology 2025 Annual Scientific Session, John W. Ostrominski, MD, of Brigham and Women’s Hospital, dives into the nuanced safety profile of finerenone for high-risk ...

The FDA approved Kerendia in July 2021 for adults with chronic kidney disease associated with Type 2 diabetes to reduce the ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for Kerendia (finerenone) to treat a new indication. The sNDA seeks approval ...

The efficacy of finerenone was consistent regardless of atrial fibrillation status in this study. New-onset atrial fibrillation was ...

Among patients with heart failure with mildly reduced ejection fraction/heart failure with preserved ejection fraction in the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in ...

Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA ...

The need to intensify oral diuretic therapy in patients who have heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) is significantly decreased with finerenone (Kerendia; ...

Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure in the EU, fulfilling a key 2025 pipeline objective. The pharma group ...

The efficacy of finerenone was consistent regardless of atrial fibrillation status in this study. New-onset atrial fibrillation was associated with a substantially higher risk of subsequent outcomes.